CTOs on the Move

Magellan Medicaid Administration

www.magellanmedicaid.com

 
Magellan Medicaid Administration is a Glen Allen, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Revolution Health Group

Revolution Health Group LLC is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VITAS Healthcare

VITAS Innovative Hospice Care, a pioneer and leader in the hospice movement since 1978, is the one of the nations largest providers of end-of-life care.

Accuray

Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company`s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Stratum Health System

Stratum Health System is a nonprofit, integrated network providing care and support to people facing chronic or advanced illness. The Stratum family of companies helps patients live as comfortably and meaningfully as possible and offers assistance to their families and caregivers along the way. As their illness advances, Stratum offers a layer of medical and emotional support services that provides compassionate care across the continuum.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.